Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here for more information

Sign In to gain access to subscriptions and/or personal tools.
Journal of Biomolecular Screening
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (13)
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Bradley, J.
Right arrow Articles by Williams, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bradley, J.
Right arrow Articles by Williams, C.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Development and Automation of a 384-Well Cell Fusion Assay to Identify Inhibitors of CCR5/CD4-Mediated HIV Virus Entry

Joe Bradley

Laboratory Automation Group (LAG)

Jasween Gill

Francois Bertelli

Sara Letafat

Hit Discovery Group (HDG)

Romu Corbau

Anti-infectives Biology, Pfizer Global Research and Development, Kent, UK

Paul Hayter

Paula Harrison

Andy Tee

Hit Discovery Group (HDG)

Wilma Keighley

Laboratory Automation Group (LAG)

Manos Perros

Anti-infectives Biology, Pfizer Global Research and Development, Kent, UK

Giuseppe Ciaramella

Hit Discovery Group (HDG)

Andreas Sewing

Laboratory Automation Group (LAG)

Christine Williams

Hit Discovery Group (HDG)chris_williams{at}sandwich.pfizer.com

This article describes the automation of an in vitro cell-based fusion assay for the identification of novel inhibitors of receptor mediated HIV-1 entry. The assay utilises two stable cell lines: one expressing CD4, CCR5 and an LTR-promoter/ß-galactosidase reporter construct, and the other expressing gp160 and tat. Accumulation of ß-galactosidase can only occur following fusion of these two cell lines via the gp160 and receptor mediators, as this event facilitates the transfer of the tat transcription factor between the two cell types. Although similar cell fusion systems have been described previously, they have not met the requirements for HTS due to complexity, throughput and reagent cost. The assay described in this article provides significant advantage, as (a) no transfection/infection events are required prior to the assay, reducing the potential for variability, (b) cells are mixed in solution, enhancing fusion efficiency compared to adherent cells, (c) miniaturisation to low volume enables screening in 384-well plates; and (d) online cell dispensing facilitates automated screening. This assay has been employed to screen ~650,000 compounds in a singleton format. The data demonstrate that the assay is robust, with a Z' consistently above 0.6, which compares favourably with less complex biochemical assays.

Key Words: HIV • HTS • gp120 • CD4 • CCR5

Journal of Biomolecular Screening, Vol. 9, No. 6, 516-524 (2004)
DOI: 10.1177/1087057104264577
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 J Biomol ScreenHome page
C. Ji, J. Zhang, N. Cammack, and S. Sankuratri
Development of a Novel Dual CCR5-Dependent and CXCR4-Dependent Cell-Cell Fusion Assay System with Inducible gp160 Expression
J Biomol Screen, February 1, 2006; 11(1): 65 - 74.
[Abstract] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
P. Dorr, M. Westby, S. Dobbs, P. Griffin, B. Irvine, M. Macartney, J. Mori, G. Rickett, C. Smith-Burchnell, C. Napier, et al.
Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity
Antimicrob. Agents Chemother., November 1, 2005; 49(11): 4721 - 4732.
[Abstract] [Full Text] [PDF]